Discovery of a Novel Trifluoromethyl Diazirine Inhibitor of SARS‐CoV‐2 Mpro

SARS‐CoV‐2 Mpro is a chymotrypsin‐like cysteine protease playing a relevant role during the replication and infectivity of SARS‐CoV‐2, the coronavirus responsible for COVID‐19. The binding site of Mpro is characterized by the presence of a catalytic Cys145 which carries out the hydrolytic activity of the enzyme. As a consequence, several Mpro inhibitors have been proposed to date in order to fight the COVID‐19 pandemic. In our work, we designed, synthesized and biologically evaluated MPD112, a novel inhibitor of SARS‐CoV‐2 Mpro bearing a trifluoromethyl diazirine moiety. MPD112 displayed in vitro inhibition activity against SARS‐CoV‐2 Mpro at a low micromolar level (IC50 = 4.1 μM) in a FRET‐based assay. Moreover, an inhibition assay against PLpro revealed lack of inhibition, assuring the selectivity of the compound for the Mpro. Furthermore, the target compound MPD112 was docked within the binding site of the enzyme to predict the established intermolecular interactions in silico. MPD112 was subsequently tested on the HCT‐8 cell line to evaluate its effect on human cells’ viability, displaying good tolerability, demonstrating the promising biological compatibility and activity of a trifluoromethyl diazirine moiety in the design and development of SARS‐CoV‐2 Mpro binders.